知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

300 条记录 (耗时 0.026 秒)

    PREDICTION OF RECURRENCE FOR BLADDER CANCER BY A PROTEIN SIGNATURE IN TISSUE SAMPLES
    92.
    发明申请
    PREDICTION OF RECURRENCE FOR BLADDER CANCER BY A PROTEIN SIGNATURE IN TISSUE SAMPLES 有权
    通过组织样品中的蛋白质标志预测刮板癌的复发

    公开(公告)号：US20140193927A1

    公开(公告)日：2014-07-10

    申请号：US14124580

    申请日：2012-06-08

    申请人： Christoph Schröder ,  Harish Srinivasan ,  Jörg Hiheisel ,  François Radvanyi

    发明人： Christoph Schröder ,  Harish Srinivasan ,  Jörg Hiheisel ,  François Radvanyi

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57407 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

    摘要： The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.

    摘要翻译： 本发明涉及癌症预测领域。 具体地说，本发明涉及一种用于预测膀胱癌治疗后受试者膀胱癌复发风险的方法，包括以下步骤：确定选自表中所示生物标志物的至少一种生物标志物的量，并比较所述 至少一种具有所述至少一种生物标志物的参考量的生物标志物，由此预测膀胱癌复发的风险。 本发明还考虑了用于鉴定需要进一步膀胱癌治疗的受试者的方法。 此外，还包括用于执行所述方法的诊断装置和试剂盒。

    Methods predicting risk of an adverse clinical outcome
    94.
    发明授权
    Methods predicting risk of an adverse clinical outcome 有权
    预测不良临床结局风险的方法

    公开(公告)号：US08728742B2

    公开(公告)日：2014-05-20

    申请号：US13422574

    申请日：2012-03-16

    申请人： James V. Snider

    发明人： James V. Snider

    IPC分类号： G01N33/53 ,  G01N33/68 ,  C07K14/47

    CPC分类号： G01N33/6893 ,  C07K14/47 ,  C07K14/4726 ,  C07K14/715 ,  G01N33/53 ,  G01N33/68 ,  G01N33/6869 ,  G01N2333/4724 ,  G01N2333/7155 ,  G01N2800/32 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

    摘要： Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation 5 in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 and a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the in the methods described.

    摘要翻译： 提供了评估受试者的不良临床结果的风险的方法，决定是否释放或继续治疗受试者（例如在住院患者），或开始或终止治疗，选择受试者参与临床 研究和选择包括确定来自受试者的生物样品中的ST2水平和半乳凝素-3水平的受试者的治疗性治疗。 还提供了包含特异性结合ST2的抗体，特异性结合半乳凝素-3的抗体以及在所述方法中使用说明书的试剂盒。

    BONE MARROW-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND ENDOTHELIAL PROGENITOR CELLS AS PROGNOSTIC INDICATORS FOR CANCER
    95.
    发明申请
    BONE MARROW-DERIVED HEMATOPOIETIC PROGENITOR CELLS AND ENDOTHELIAL PROGENITOR CELLS AS PROGNOSTIC INDICATORS FOR CANCER 有权
    骨巨细胞病毒致死原体细胞和内皮祖细胞作为癌症的预后指标

    公开(公告)号：US20140134190A1

    公开(公告)日：2014-05-15

    申请号：US14001249

    申请日：2012-02-24

    申请人： Linda Vahdat ,  Shahin Rafii ,  Rakhi Naik ,  Maureen Lane ,  Vivek Mittal

    发明人： Linda Vahdat ,  Shahin Rafii ,  Rakhi Naik ,  Maureen Lane ,  Vivek Mittal

    IPC分类号： G01N33/68 ,  C07K16/28

    CPC分类号： G01N33/6893 ,  C07K16/2863 ,  G01N33/56966 ,  G01N33/574 ,  G01N2800/52 ,  G01N2800/54

    摘要： Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1+ hematopoietic progenitor cells (HPCs) and/or VEGFR2+ endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.

    摘要翻译： 确定患有癌症进展或癌症复发风险的受试者的癌症进展或癌症复发的方法，所述方法包括：从所述受试者获得样品; 测量所述样品中VEGFR1 +造血祖细胞（HPC）和/或VEGFR2 +内皮祖细胞（EPCs）的水平; 并在一个或多个以后的时间点接受额外的样品并进行其他测量的HPCs和/或EPCs。 从测量结果可以看出，相对于较早的测量，可以确定在至少一个以后的测量中HPC和/或EPC水平是否有所升高。 HPC和/或EPCs水平的激增表明所述受试者的癌症进展或复发的风险增加。

    METHOD OF PREDICTING THE EVOLUTION OF A PATIENT SUFFERING OF STROKE
    96.
    发明申请
    METHOD OF PREDICTING THE EVOLUTION OF A PATIENT SUFFERING OF STROKE 审中-公开
    预测患者卒中发展的方法

    公开(公告)号：US20140045198A1

    公开(公告)日：2014-02-13

    申请号：US14001006

    申请日：2012-02-20

    申请人： Joan Montaner Villalonga ,  Anna Rosell Novel ,  Miriam Navarro Sobrino

    发明人： Joan Montaner Villalonga ,  Anna Rosell Novel ,  Miriam Navarro Sobrino

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N33/6896 ,  G01N2333/515 ,  G01N2333/70575 ,  G01N2800/2871 ,  G01N2800/54 ,  G01N2800/56

    摘要： The invention is a method of predicting the evolution of a patient suffering of a neurovascular disease, preferably stroke, comprising obtaining a biological sample of said patient, assessing in said biological sample the level of endostatin and FasL, determining whether said levels of endostatin and FasL together are above or below predetermined cut-off levels and predicting the functional outcome of said neurovascular disease on said patient evaluating the result of the previous step. The combination of endostatin and FasL is a more powerful predictor that any clinical prognostic tool and adds significant prognostic value to all other clinical variables of the art.

    摘要翻译： 本发明是一种预测患有神经血管疾病，优选中风的患者的进展的方法，包括获得所述患者的生物样品，在所述生物样品中评估内皮抑制素和FasL的水平，确定所述内皮抑素和FasL的水平是否 一起高于或低于预定的截止水平，并且对所述患者的所述神经血管疾病的功能结果进行预测，以评估前一步骤的结果。 内皮抑素和FasL的组合是任何临床预后工具的更强大的预测因子，并为本领域的所有其他临床变量增加显着的预后价值。